Devin Haddad

Devin Haddad

Auto-generated profile, based on publicly available information

Devin Haddad

Cardio-oncology Program, Division of Cardiology, The Ohio State University Medical Center, Columbus, OH; and

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 November 2019 in Blood
Verified
Journal Article
Open access
PDF file
TDTyler Dickerson
Tyler Dickerson
TWTracy Wiczer
Tracy Wiczer
AWAllyson Waller
Allyson Waller
JPJennifer Philippon
Jennifer Philippon
KPKyle Porter
Kyle Porter
DADaniel Addison
Daniel Addison
In a retrospective analysis, Dickerson et al report that the incidence of hypertension in patients treated with ibruitinib is nearly 80% and is associated with an increased rate of adverse cardiovascular events, primarily atrial fibrillation. Cardiac events can be reduced by treating the hypertension.

4 May 2017 in Journal of Cardiovascular Electrophysiology
Verified
Journal Article
Open access
PDF file
Avirup GuhaAvirup Guha
Avirup Guha
XXXiao Xiang
Xiao Xiang
DHDevin Haddad
Devin Haddad
BBBenjamin Buck
Benjamin Buck
XGXu Gao
Xu Gao
EDEmile G. Daoud
Emile G. Daoud
Background: Pacemakers (PM) are used for managing sick sinus syndrome (SSS). This study evaluates predictors and trends of PM implantation for SSS.Methods: Patients were identified from the National Inpatient Sample dataset (2003–2013). Included patients were ≥18 years old, had a diagnosis of sinus node dysfunction and atrial arrhythmia (i.e., SSS). Patients who died, transferred out, who had prior device, or had a defibrillator or resynchronization therapy device implanted were excluded. Included patients were then stratified by if a PM was implanted. Data regarding SSS, trends of PM utilization, and multivariable models of factors associated with PM implantation are presented.Results: Note that 328,670 patients satisfied study criteria. This study compared patients who underwent (87.4%) PM implantation to those who did not undergo (12.6%) PM implantation. The annual trends for hospitalization with SSS and PM placement have been decreasing (P <0.001). Variables associated with lower likelihood for PM implantation include young age, female sex, non‐Caucasian race, chronic heart failure, Charlson Comorbidity Score ≥1, emergency room and weekend admission, hospital stay ≤3 days, and high cardiology inpatient volume. Greater likelihood for PM implantation was associated with hyperlipidemia, hypertension, and hospitals that were either private, large, Northeastern location, or with high cardiac procedural volume.Conclusions: Analyzing 11‐year data from a national inpatient database demonstrate a number of relevant variables that impact PM utilization that include not only clinical but also nonclinical variables such as socioeconomic status, gender, and hospital features. Racial and gender bias toward PM implantation are unchanged and persist through 2013.

1 April 2017 in Urology
Verified
Journal Article
Closed access
SMSusan MacDonald
Susan MacDonald
DHDevin Haddad
Devin Haddad
ACAbraham Choi
Abraham Choi
MCMarc Colaco
Marc Colaco
RTRyan Terlecki
Ryan Terlecki

20 June 2017 in EP Europace
Verified
Journal Article
Open access
PDF file
DHD. Haddad
D. Haddad
DPD. Patel
D. Patel
MAM. Afzal
M. Afzal
HGH. Godara
H. Godara
ABA. Badin
A. Badin
TOT. Okabe
T. Okabe
Background: Transcatheter aortic valve replacement (TAVR) can lead to atrioventricular (AV) conduction changes and need for permanent pacemaker (PPM) implantation. There is currently no consensus on clinical decision making for PPM evaluation in patients undergoing TAVR.